Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
about
Molecular biology of lung cancerTyrosine Kinase Receptor Landscape in Lung Cancer: Therapeutical ImplicationsUnderstanding and Targeting MET Signaling in Solid Tumors - Are We There Yet?Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistanceRole of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agentsOncogenic RIT1 mutations in lung adenocarcinoma.Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skippingFusion gene and splice variant analyses in liquid biopsies of lung cancer patientsTargeted Therapies in Non-Small Cell Lung Cancer-Beyond EGFR and ALKBiology of MET: a double life between normal tissue repair and tumor progressionTargeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulationDorsal ruffle microdomains potentiate Met receptor tyrosine kinase signaling and down-regulation.CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.Molecular pathways and therapeutic targets in lung cancerReview of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice.Emerging molecular targets in oncology: clinical potential of MET/hepatocyte growth-factor inhibitors.ALK-rearrangements and testing methods in non-small cell lung cancer: a reviewNon-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's PerspectiveTargeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor.Targeting MET Amplification as a New Oncogenic Driver.Increased MET Gene Copy Number but Not mRNA Level Predicts Postoperative Recurrence in Patients with Non-Small Cell Lung CancerSynergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinibTranscriptome meta-analysis of lung cancer reveals recurrent aberrations in NRG1 and Hippo pathway genes.Genome-wide discovery of human splicing branchpointsMechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.Lung cancer molecular epidemiology in China: recent trendsAlternative splicing in oncogenic kinases: from physiological functions to cancerc-Met in esophageal squamous cell carcinoma: an independent prognostic factor and potential therapeutic targetTargetable "driver" mutations in non small cell lung cancer.Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular proteinc-MET immunostaining in colorectal carcinoma is associated with local disease recurrenceCorrelation between MET gene copy number by silver in situ hybridization and protein expression by immunohistochemistry in non-small cell lung cancer.Genetic and biochemical alterations in non-small cell lung cancer.EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).Review of the treatment of non-small cell lung cancer with gefitinib.Value of c-Met for Predicting Progression of Precancerous Gastric Lesions in Rural Chinese Population.MET as a possible target for non-small-cell lung cancer.Has MET met its match?Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.MET Exon 14 Skipping in Non-Small Cell Lung Cancer.
P2860
Q24606677-30954635-E8D9-46C2-BDEF-879A827D6F89Q26741318-69FEBC7F-1C75-4DA3-82AC-252041F05B74Q26748581-8E65981A-BCAB-4B11-987D-1E6FEAF3DA03Q26799900-BA9402EC-026D-4B65-8F55-706B4D17A263Q27027957-3622940D-F222-4C8E-A674-49CD3D853312Q27852800-E8A111BB-C2BF-4F1E-898D-CB3D94C75A42Q27853167-D50502F2-7C55-411A-B9EA-5B08EFD596A6Q28079245-AD210CD1-3D60-4A0C-B7A4-DC8646BFDC16Q28083446-36C9EB20-D47B-420F-B0E6-44B7980F895DQ28085247-662ADF61-E45E-4E54-BEC1-464B76AE8DFAQ28513426-248EB70A-27D8-4770-AE4B-0BC28D758E99Q30495866-70EC7158-4A78-4284-BBD0-54F71202D97BQ33528991-7156E6DF-8AAB-4FB5-9784-035F004AB440Q33688872-453823E5-A05E-4E35-85CB-BF6145376892Q33757138-1248DD20-50A6-40B1-AA7B-8792F4ECC93DQ33769437-5E20E355-0406-486C-8F88-7FBBB23861C1Q33776835-A315F400-3695-4E4E-9444-14EF3AD336CBQ33906921-4279FAF5-81B7-4F19-A8ED-3712C99B9137Q34158153-7B9C2987-5B1C-4F63-9384-54D5079393AAQ34309927-C2D73BF7-E25A-485D-B43D-88B7B8027340Q34478374-2FA169F1-F3BF-4494-B315-25BA8687B8E9Q34635475-02E0BAA2-FE37-4652-A748-6E70809AA93BQ34762165-E81AEFD4-5DEF-4E6A-AC77-DA17185E27ACQ35042993-12D130FD-7B5A-466D-B7BA-4F5258F0B5A8Q35043706-A546A2F5-AFC5-42AD-A622-E1F286A3E14AQ35200702-6F485E22-D8D0-4441-8411-10FB7112FCEAQ35295203-1EB82A1B-2948-4CFB-8741-32D727231184Q35650167-83FB0EB1-5145-4B48-AF07-0637E51959CEQ35737325-3BA0511B-0A6D-42A3-BEB9-8CABCF1AF2A3Q35747784-6A756362-5943-44FF-A96F-7BED481057B3Q35804089-8651D0D8-5082-43D4-A85D-B39A4539F212Q35983145-806F1B29-7944-454E-914F-EE0EC64E9BC5Q36184584-8DCED807-62F1-48C2-99F1-AD6BA00C4CB8Q36250691-3A9D6DB3-62C8-43D6-95AF-A896EA10E2C1Q36461805-AF56756F-6FDF-4302-80E0-31CF9767C117Q36563092-9770BCC7-9BCA-4A34-AC90-6144A2A59A5BQ36660673-FEBD809D-D6D2-4E1A-A6C8-EA5DE82EC50DQ36685708-D361CF2B-8C66-40B3-B2AA-AAF1511178F5Q36729516-533EDB53-CD73-4CFD-8348-668F46835238Q36788312-990CDB52-A274-4245-97F0-30F2D8BF057E
P2860
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh
2009年學術文章
@zh-hant
name
Activation of MET by gene ampl ...... primary resected lung cancers.
@en
Activation of MET by gene ampl ...... primary resected lung cancers.
@nl
type
label
Activation of MET by gene ampl ...... primary resected lung cancers.
@en
Activation of MET by gene ampl ...... primary resected lung cancers.
@nl
prefLabel
Activation of MET by gene ampl ...... primary resected lung cancers.
@en
Activation of MET by gene ampl ...... primary resected lung cancers.
@nl
P2093
P1476
Activation of MET by gene ampl ...... primary resected lung cancers.
@en
P2093
Hiroyuki Kuwano
Ryoichi Onozato
Takayuki Kosaka
Yoshitaka Sekido
P356
10.1097/JTO.0B013E3181913E0E
P577
2009-01-01T00:00:00Z